Table 2 Demographic and clinical characteristics and response to SSRI.

From: Treatment of 95 post-Covid patients with SSRIs

 

Total (n = 95)

Open question outcome (n = 93)

Group differences

0 (n = 9)

1 (n = 25)

2 (n = 25)

3 (n = 27)

4 (n = 7)

Age (min–max)

43.5 (21–72)

47.7 (25–72)

44.3 (21–68)

43.1 (22–62)

40.7 (25–58)

46.3 (30–57)

No (BF = 0.13)

Gender (f/m)

80/15

8/1

19/6

21/4

24/3

6/1

~ (BF = 0.34)

Hospitalization during COVID

3 (3.2%)

3 (33.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Yes (BF = 16.4)

Medical history

 Auto-immune diseases

9 (9.5%)

1 (11.1%)

2 (8.0%)

4 (16.0%)

1 (3.7%)

0 (0.0%)

~ (BF = 0.48)

 Asthma/allergies

46 (48.4%)

2 (22.2%)

14 (56.0%)

15 (60.0%)

12 (44.4%)

3 (42.9%)

No (BF = 0.22)

 Pfeiffer/Dengue

3 (3.2%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

3 (11.1%)

0 (0.0%)

~ (BF = 1.05)

 Connective tissue disorders

10 (10.5%)

1 (11.1%)

5 (20.0%)

3 (12.0%)

1 (3.7%)

0 (0.0%)

~ (BF = 1.05)

 ME/CVS

3 (3.2%)

0 (0.0%)

1 (4.0%)

1 (4.0%)

1 (3.7%)

0 (0.0%)

~ (BF = 0.47)

 Factor V Leiden Thrombophilia

2 (2.1%)

0 (0.0%)

1 (4.0%)

1 (4.0%)

0 (0.0%)

0 (0.0%)

~ (BF = 0.58)

 Psychiatric disorders: anxiety, panic, depression, or AD(H)D

7 (7.4%)

1 (11.1%)

0 (0.0%)

3 (12.0%)

2 (7.4%)

0 (0.0%)

~ (BF = 0.38)

 Time gap in months between start PCS and SSRI (min–max)

15 (3–36)

20 (9–34)

16 (3–31)

14 (3–36)

14 (6–33)

15 (3–26)

No (BF = 0.18)

SSRI type: sigma1 agonists

 Citalopram

46 (48.4%)

4 (44.4%)

10 (40.0%)

17 (68.0%)

13 (48.1%)

2 (28.6%)

No (BF = 0.096)

 Fluvoxamine

15 (15.8%)

2 (22.2%)

2 (8.0%)

3 (12.0%)

2 (7.4%)

4 (57.1%)

 Venlafaxine

17 (17.9%)

2 (22.2%)

7 (28.0%)

2 (8.0%)

5 (18.5%)

1 (14.3%)

 Escitalopram

10 (10.5%)

1 (11.1%)

4 (16.0%)

1 (4.0%)

4 (14.8%)

0 (0.0%)

 Fluoxetine

2 (2.1%)

0 (0.0%)

1 (4.0%)

0 (0.0%)

1 (3.7%)

0 (0.0%)

SSRI type: Sigma 1 antagonists

      

 Sertraline/Paroxetine

5 (5.4%)

0 (0.0%)

1 (4.0%)

2 (8.0%)

2 (7.4%)

0 (0.0%)

  1. The column ‘Group differences’ indicates the amount of evidence for a group difference (BF > 1) or no group difference (BF < 1) between the 5 groups on the respective characteristic. ~ indicates no strong evidence in either direction (i.e., BF between 1/3 and 3). The effect of SSRI type on open question outcome is tested in a single Bayesian ANOVA. Note that one patient initially used sertraline (outcome 0) but switched to citalopram (outcome 2).
Back to article page